In short. What the assessment after a filler complication establishes, why the substance class comes first, and how the findings decide what is done and in what order.

Key points

  • Before any plan is made, establish whether the material can be dissolved.
  • Where it can, reversal is often the first and simplest step.
  • Where it cannot, the management is directed at the tissue response, the symptoms and the appearance, over months rather than in one session.

A filler complication is assessed rather than guessed at, and the assessment follows a definite order. The first question is not what the problem looks like but what was put into the tissue, because that determines which treatments are even available. Only after that does the examination of the problem itself decide what is done.

What was injected, where and when

The substance class, the areas treated, the date, and how many previous injections have been performed in the same place. The class is the single most useful fact, because it decides whether dissolving is available: hyaluronic-acid filler can be dissolved with an enzyme, and calcium hydroxylapatite, poly-L-lactic acid and polynucleotides cannot. If the product is unknown, that is recorded rather than assumed, because it changes what is safe to do.

Examination of the skin and the tissue

The colour and temperature of the skin over the treated area, the pattern of any discolouration, whether there is pain out of proportion, the state of the tissue, and the presence of any lump. A vascular problem is a clinical diagnosis made at the bedside, not a laboratory one, which is why the examination is done immediately when the signs suggest it.

The substance class decides the options

Before any plan is made, establish whether the material can be dissolved. Where it can, reversal is often the first and simplest step. Where it cannot, the management is directed at the tissue response, the symptoms and the appearance, over months rather than in one session.

Infection, excluded or treated first

Redness, heat, pain, fever or a collection change the order of everything. An infection is treated before the appearance is addressed, because correcting a lump while an infection or a biofilm is active leads to recurrence. Where a collection is present it is sampled or drained rather than left, and the sample is what identifies what is growing.

Lumps and delayed reactions

A lump may be unintegrated product, a collection, an inflammatory nodule or an infection, and the history and examination distinguish them. A delayed reaction raises the same question, with the addition that a biofilm has to be considered when a reaction settles and then returns.

Documentation

What was injected, by whom, when, what was found and what was done. This matters beyond the current episode. A complication that is recorded can be managed consistently if it recurs, and it allows another clinician to help without starting from nothing — which is particularly important where the original treatment was performed elsewhere.

What you should leave with

Clear answers: what the problem is, whether it is urgent, what can be done about it, in what order, and what the expected course is. And an honest statement of what cannot be undone — because some complications leave changes that are improved rather than reversed, and a plan that does not say so is not an honest plan.

Seek care rather than waiting if

  • Severe pain out of proportion to the injection, or skin turning white, grey, mottled or dusky — a vascular emergency; contact your treating team now, and if the team cannot be reached go to the nearest emergency department immediately.
  • Any change in vision — seek emergency care immediately.
  • A fever, a spreading redness, blistering or skin breakdown over a treated area.

Related reading

Frequently asked questions

Why does it matter what I was injected with?

Because it decides what can be done. Hyaluronic-acid filler can be dissolved with an enzyme; calcium hydroxylapatite, poly-L-lactic acid and polynucleotides cannot. That single fact changes the plan more than any other, so establishing it comes first.

What if I was injected somewhere else?

You can still be assessed. A tertiary hospital assesses complications after treatment performed elsewhere routinely. Bring whatever record you have, say where and when the injection was done, and say what you know about the product.

Does every complication need imaging or tests?

No. Many are diagnosed by history and examination. Tests are used where the question is specific: whether there is an infection, whether a lump is a collection or something else, or whether the tissue beneath the skin is involved.

Risks & Limitations

  • Vascular occlusion — filler blocking a blood vessel. This is a time-critical emergency that can cause skin loss and, rarely, vision loss.
  • Skin injury, blistering or a dusky patch over a treated area.
  • Nodules, lumps or delayed inflammatory reactions, which may need treatment or dissolving.
  • Infection at an injection site, including a deep collection that needs drainage.
  • Filler that has migrated away from the intended area.
  • Asymmetry or over-correction, which is harder to correct than under-correction.
  • An unknown product, which changes what can be done and how quickly.

When to Seek Care

  • Severe pain out of proportion to the injection, or skin turning white, grey, mottled or dusky — a vascular emergency; contact your treating team now, and if the team cannot be reached go to the nearest emergency department immediately.
  • Any change in vision — seek emergency care immediately.
  • Fever, spreading redness, warmth or pus at an injection site.
  • A hard, painful lump that is growing, or redness and swelling appearing weeks to months after treatment.
  • Skin breakdown or blistering over a treated area.

References & Further Reading

  • American Academy of Dermatology (AAD) — injectable safety information
  • American Society of Plastic Surgeons (ASPS) — dermal filler guidance
  • U.S. Food and Drug Administration (FDA) — approved dermal filler products
  • National Medical Products Administration (NMPA, China) — approved product status
  • Chongqing West District Hospital — Plastic Surgery & Aesthetics Medical Center

Medically reviewed by Ke He, MD (何锞), Deputy Director & Head of Skin & Laser Aesthetics. Last reviewed: 19 September 2026.

This page is patient education, not medical advice, and it does not cite individual studies. Discuss your own case with a qualified clinician. To arrange an assessment at Chongqing West District Hospital, see Contact & Consultation.